Heartflow (NASDAQ:HTFL) CEO Sells $643,017.00 in Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of the company’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $28.50, for a total transaction of $643,017.00. Following the transaction, the chief executive officer owned 496,835 shares in the company, valued at approximately $14,159,797.50. The trade was a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Monday, May 11th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $29.12, for a total transaction of $657,005.44.
• On Friday, April 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $26.72, for a total transaction of $602,856.64.
• On Wednesday, March 18th, John C.M. Farquhar sold 9,725 shares of Heartflow stock. The shares were sold at an average price of $25.00, for a total transaction of $243,125.00.

Heartflow Stock Performance

Shares of NASDAQ:HTFL traded up $2.57 during mid-day trading on Friday, reaching $33.24. The stock had a trading volume of 1,889,853 shares, compared to its average volume of 1,165,800. The firm has a 50 day simple moving average of $29.30 and a two-hundred day simple moving average of $28.34. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $41.22.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The firm had revenue of $52.59 million during the quarter. The business’s quarterly revenue was up 41.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Heartflow, Inc. will post -0.82 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating on shares of Heartflow in a research report on Thursday. William Blair assumed coverage on shares of Heartflow in a research report on Monday, May 4th. They issued an “outperform” rating on the stock. Wells Fargo & Company increased their price target on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. JPMorgan Chase & Co. cut their price target on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, March 19th. Finally, Canaccord Genuity Group dropped their target price on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.00.

Institutional Trading of Heartflow

Hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd acquired a new stake in Heartflow during the 4th quarter worth approximately $27,000. Russell Investments Group Ltd. acquired a new stake in Heartflow during the 4th quarter worth approximately $45,000. Essential Partners LLC acquired a new stake in Heartflow during the 1st quarter worth approximately $57,000. Legal & General Group Plc acquired a new stake in Heartflow during the 3rd quarter worth approximately $59,000. Finally, Strs Ohio acquired a new stake in Heartflow during the 4th quarter worth approximately $99,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.